Company Overview - Acuity Brands Lighting (ABL) net sales were $3612 million in FY25 and $3621 million in LTM Q1'26[46] - Acuity Intelligent Spaces (AIS) net sales were $764 million in FY25 and $948 million in LTM Q1'26[47] Financial Performance - The company's net sales have grown from $17 billion in FY09 to $4538 billion in LTM Q1'26[34, 42] - Adjusted operating profit increased from $196 million in FY09 to $806 million in LTM Q1'26[35, 42] - Adjusted diluted earnings per share increased from $274 in FY09 to $1873 in LTM Q1'26[37] - Free cash flow increased from $72 million in FY09 to $534 million in LTM Q1'26[38, 44] Capital Allocation - The company has repurchased approximately $15 billion of its shares outstanding from the beginning of the 4th quarter of 2020, representing approximately 25% of the then-outstanding shares[31] ABL Performance - ABL Adjusted Operating Profit was $662 million in FY25 and $669 million in LTM Q1'26[23, 46] - ABL Adjusted Operating Profit Margin was 183% in FY25 and 185% in LTM Q1'26[23, 46] AIS Performance - AIS Adjusted Operating Profit was $164 million in FY25 and $206 million in LTM Q1'26[28, 47] - AIS Adjusted Operating Profit Margin was 215% in FY25 and 217% in LTM Q1'26[28, 47]

Financial Data and Key Metrics Changes - Total sales for Q1 2026 were $73.5 million, up from $64.5 million in the prior year, with comparable sales growth of negative 2.5% [5][10] - Cost of goods sold as a percentage of sales increased to 29.9% from 29% in the prior year quarter, influenced by tariffs [5][11] - Labor costs as a percentage of sales decreased to 32.5% from 32.9% in the prior year, due to operational initiatives [5][11] - Net loss for the quarter was $3.1 million, or negative $0.25 per share, compared to a net loss of $1 million, or negative $0.08 per share in the prior year [12][13] - Adjusted net loss was $2.8 million, or negative $0.23 per share, compared to an adjusted net loss of $1 million, or negative $0.08 per share in the prior year [13] Business Line Data and Key Metrics Changes - The company opened four new restaurants in Q1 2026, with ten more under construction [6] - Restaurant-level operating profit as a percentage of sales was 15.1%, down from 18.2% in the prior year quarter [13] Market Data and Key Metrics Changes - Comparable sales in the West Coast market were negative 2.8%, and in the Southwest market, they were negative 2.7% [10] - Effective pricing for the quarter was 3.5%, with expectations for the second quarter to be 4.5% [10] Company Strategy and Development Direction - The company aims to open 16 new restaurants in fiscal 2026, maintaining an annual unit growth rate above 20% [14] - The company is focusing on aggressive cost management, reducing G&A as a percentage of sales by 80 basis points on an adjusted basis [4] - Marketing efforts include a campaign with Kirby, coinciding with the release of Kirby Air Riders for Switch 2, and the introduction of a reservation system [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving qualitative comparable sales for the year, with expectations for positive comps in Q2 [4][23] - The company noted that the first quarter created a strong foundation for growth, with momentum continuing into December [5][23] - Management acknowledged the impact of tariffs on costs but expressed optimism about negotiations with suppliers mitigating some of the pressures [28][81] Other Important Information - The company has $78.5 million in cash and no debt, indicating strong liquidity [13] - General and administrative expenses as a percentage of sales were 13%, down from 13.5% in the prior year quarter [12] Q&A Session Summary Question: Discussion on decoupling the reservation system from loyalty - Management reported that over half of visits by rewards members are through the reservation system, indicating better-than-expected uptake [19] Question: Expectations for Q2 comps - Management expects positive comps for Q2, citing strong performance in November and December [23] Question: Impact of tariffs on food costs - Management indicated that it takes 4-6 months to see the impact of tariff changes on food costs due to inventory cycles [27] Question: Future promotions and collaborations - Management confirmed ongoing promotions with Kirby and upcoming collaborations with Sanrio and Jujutsu Kaisen [88] Question: Long-term growth target - Management did not revise the long-term growth target of 300 units in the U.S. but will provide updates as necessary [78]

Immuneering Conference Call Summary Company Overview - **Company**: Immuneering - **Focus**: Development of atebumetanib for treating first-line pancreatic cancer Key Industry Insights - **Industry**: Oncology, specifically pancreatic cancer treatment - **Current Treatment Landscape**: Standard of care includes gemcitabine plus nab-paclitaxel (GNP), with overall survival rates significantly lower than those reported for atebumetanib Core Points and Arguments 1. **Overall Survival Data**: - 12-month overall survival rate for patients treated with atebumetanib plus chemotherapy is 64% [7][21] - Historical benchmark for standard of care (GNP) is approximately 35%, indicating a 29-point absolute separation [8][21] - Median overall survival for standard of care is about 8.5 months, while median for atebumetanib has not yet been reached [8][11] 2. **Quality of Life Improvements**: - Significant improvements in quality of life reported, with specific case studies highlighting patients regaining independence and experiencing less severe side effects [5][18] - Functional Assessment of Anorexia Cachexia Therapy (FAACT) score improved from 96 to 141 in a patient case study [18] 3. **Safety and Tolerability**: - Favorable safety profile with few severe side effects; only anemia and neutropenia occurred in over 10% of patients [10] - No harsh side effects observed with atebumetanib monotherapy, differentiating it from traditional chemotherapy [10] 4. **Clinical Trial Plans**: - Upcoming pivotal phase 3 trial (MapKeeper 301) will enroll approximately 510 patients, comparing atebumetanib plus modified gemcitabine nab-paclitaxel against standard GNP [20] - Primary endpoint will be overall survival, with dosing expected to begin mid-year [20] 5. **Expanded Cohort Data**: - An expanded cohort of over 50 patients is being reported, with overall survival trending consistently with the original cohort of 34 patients [12][49] - The expanded cohort includes additional patients who started treatment later, but results remain robust [49] 6. **Market Positioning**: - Immuneering aims to position atebumetanib as a best-in-class treatment for pancreatic cancer, with the potential to become the new standard of care [52] - The company emphasizes the importance of both quality and quantity of life for patients, aiming to provide effective treatment without debilitating side effects [34][52] Additional Important Content - **Patient Demographics**: The trial population is older, with a median age of 69, which reinforces the significance of the survival benefits observed [12] - **Future Milestones**: Upcoming milestones include sharing circulating tumor DNA analyses and updated survival data, as well as the initiation of phase 2 combination studies in lung cancer [21][22] This summary encapsulates the key points discussed during the Immuneering conference call, highlighting the promising data surrounding atebumetanib and its potential impact on the treatment of pancreatic cancer.

Summary of Omeros Corporation Conference Call Company Overview - **Company**: Omeros Corporation - **Product**: Yarcomlia (narsoplimab) - **Industry**: Biotechnology, specifically focused on treatments for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TATMA) Key Points FDA Approval and Product Launch - Yarcomlia received FDA approval on December 23, 2025, marking it as the first and only therapy approved for TATMA, a life-threatening complication of stem cell transplantation [3][4] - The approval is a significant milestone for Omeros, being their second FDA-approved product after Omidria [4] - The commercial launch of Yarcomlia began on January 2, 2026, with a fully trained commercial team reaching out to U.S. transplant centers [9][10] Clinical Data and Efficacy - Approval was based on a pivotal trial involving 28 patients and an expanded access program with 221 patients [5] - Yarcomlia demonstrated a 61% complete response rate in the pivotal study and a 68% rate in the expanded access program [6] - The 100-day survival rate post-TMA diagnosis was 73% in the pivotal study and 74% in the expanded access program [6] - In high-risk patients who had failed other treatments, Yarcomlia achieved a 50% one-year survival rate compared to historical rates of less than 20% [8] Safety Profile - Yarcomlia has a differentiated safety profile with no box warning, no risk evaluation and mitigation strategy (REMS), and no vaccination requirement, unlike other off-label therapies [5][8] - Historical use of C5 inhibitors, such as eculizumab, has been associated with significantly higher risks of infection and mortality [9][36] Market Opportunity and Commercial Strategy - Approximately 11,000 allogeneic transplants are performed annually in the U.S., with TATMA developing in up to 56% of these cases [10][48] - Omeros plans to prioritize the top 80 transplant centers that account for about 80% of procedures [10] - The initial price for Yarcomlia is set at approximately $36,000 per vial, with median utilization expected to be 8 to 10 vials per treatment course [12] - A national ICD-10 diagnostic code for TATMA and specific CPT codes for Yarcomlia have been established to facilitate reimbursement [12][38] Reimbursement and Financial Support - Omeros has applied for a new technology add-on payment (NTAP) to assist with costs for Medicare patients, expected to be effective in October 2026 [13][25] - The company has a robust reimbursement strategy in place, including personalized assistance programs for providers [14] Future Plans and Pipeline - Omeros is evaluating partnerships for the commercialization of Yarcomlia outside the U.S. and plans to expand its indications [15] - The company aims to advance its long-acting MASP2 inhibitor, OMS 1029, and its MASP2 small molecule program [15] - The focus is on making Yarcomlia the standard of care for TATMA and ensuring reliable supply and access [43][54] Expert Insights - Experts on the call emphasized the importance of early intervention with Yarcomlia, which could lead to better patient outcomes compared to historical treatment approaches [17][19] - The shift in treatment paradigms is expected to improve overall management of TATMA patients, allowing for continued use of immunosuppressive therapies [19][22] Conclusion - The approval and launch of Yarcomlia represent a significant advancement in the treatment of TATMA, with a clear objective to establish it as the standard of care [43][54] - Omeros is committed to executing its strategy effectively to ensure patient access and improve clinical outcomes for those affected by TATMA [54]

Costco Wholesale (NasdaqGS:COST) 2025 Update Summary Company Overview - **Company**: Costco Wholesale - **Date of Call**: January 07, 2026 - **Period Covered**: Five-week retail month of December 2025 Key Financial Metrics - **Net Sales**: $29.86 billion, an increase of 8.5% from $27.52 billion last year [2] - **Comparable Sales**: - **US**: 6.0% - **Canada**: 8.4% - **Other International**: 10.6% - **Total Company**: 7.0% - **Digitally Enabled**: 18.9% [2] - **Comparable Sales Excluding Gas and FX**: - **US**: 6.3% - **Canada**: 6.0% - **Other International**: 5.6% - **Total Company**: 6.2% - **Digitally Enabled**: 18.3% [2] - **Traffic Growth**: Up 2.7% worldwide and 2.4% in the US [2] Impact of External Factors - **Foreign Currency Impact**: - Canada: Positive impact of approximately 3.5% - Other International: Positive impact of approximately 5.4% - Total Company: Positive impact of approximately 1.2% [3] - **Gas Price Deflation**: Negatively impacted total reported comparable sales by approximately 40 basis points; average worldwide selling price per gallon down 4.4% [3] Regional Performance - **Strongest US Regions**: Midwest, Northwest, and Southeast [3] - **Strongest International Markets**: Australia, Japan, and Korea [3] Merchandising Highlights - **Food and Sundries**: Positive mid-single digits - **Fresh Foods**: Up high single digits, with strong performance in bakery and meat [4] - **Non-Foods**: Positive mid-single digits, with strong performance in jewelry, tires, small appliances, and majors [4] - **Ancillary Business Sales**: Up mid-single digits, with pharmacy, food court, and optical as top performers [4] - **Gas Sales**: Down low single digits due to price per gallon changes year over year [4] Forward-Looking Statements - The company provided forward-looking statements that involve risks and uncertainties, which may cause actual results to differ from those indicated [1]

Greatness Starts Here We transform organizations by building exceptional leaders, teams, and cultures that get results. INVESTOR UPDATE First Quarter Fiscal 2026 This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward -looking statements are based upon management's current expectations and are subject to various risks and uncertainties including, but not limited to : The ability of the Company to grow revenues; The acceptanc ...

Summary of the Conference Call Company Overview - The company is an iconic Canadian firm headquartered in Waterloo, Canada, with a global presence in over 20 countries and approximately 1,700 employees, primarily based in Canada [3][2] - The company is projected to exceed $530 million in revenue this year, transitioning from a focus on cybersecurity to secure communications [3][4] - The business is structured into three main divisions: QNX, secure communications, and licensing, with QNX identified as the growth engine [3][5] Financial Performance - The company has achieved seven consecutive quarters of improving net income, with the last three quarters showing positive net income [5][6] - The operating cash flow has stabilized, moving from cash burn to sustainable cash generation, with the exception of one seasonal quarter [6][5] - The backlog for QNX has increased to $865 million, up from $460 million in Q4 2022, indicating strong growth potential [38][39] QNX Business Insights - QNX is positioned as the de facto choice for critical embedded systems across various industries, including automotive, industrial, and medical [10][20] - The launch of QNX 8 focuses on performance, scalability, and real-time capabilities without compromising safety and security [11][21] - The addressable market for QNX is expanding, with a projected threefold increase due to strategic investments [13][42] Market Trends and Opportunities - The automotive industry is shifting towards more intelligent vehicles, with increasing demand for performance and reliability [12][10] - The complexity of vehicle systems is expected to triple, creating opportunities for QNX to provide solutions [19][18] - The company has secured partnerships with top OEMs, including BMW, which has selected QNX for its new generation of vehicles featuring advanced computing capabilities [17][12] Strategic Initiatives - The introduction of Alloy Core, a joint development with Vector Informatik, aims to streamline technology integration and enhance safety and security in automotive systems [26][30] - The General Embedded Markets (GEM) segment is experiencing rapid growth, with expectations for it to contribute significantly to overall revenue [54][53] - The QNX Everywhere initiative aims to increase accessibility to QNX technology for academic and research purposes, fostering future growth [34][36] Competitive Landscape - The company emphasizes its competitive moat built on trust, proven performance, and a strong track record in safety and security certifications [20][22] - The dynamics of low-cost competition from Chinese OEMs are acknowledged, but the company maintains that safety and reliability remain paramount for global OEMs [45][50] Future Outlook - The company is optimistic about its growth trajectory, with expectations for continued double-digit growth and a strong financial profile moving towards Rule of 40 status [42][39] - The focus on innovation and strategic investments positions the company well for long-term success in both automotive and adjacent markets [40][41] Key Metrics - Revenue projection: Exceeding $530 million [3] - QNX backlog: $865 million, up from $460 million [38] - Seven consecutive quarters of improving net income [5] - Anticipated threefold increase in addressable market [13]

Summary of Primoris Services Conference Call Company Overview - **Company**: Primoris Services (NYSE: PRIM) - **Industry**: Energy Services, specifically focusing on critical infrastructure including power generation, solar, gas, transmission, distribution, and oil and gas pipelines [1][4][10] Core Points and Arguments Strategic Focus - Primoris emphasizes its role in critical energy infrastructure, with a focus on power generation, particularly in solar and gas sectors [4][10] - The company aims to be the best capital allocator in its space, supporting organic growth while considering divestitures where necessary [5] Business Evolution - Primoris has undergone a strategic plan over the past three years to focus on high-growth, high-margin businesses, particularly in solar and gas-powered generation [10] - The company has transitioned from a diversified portfolio to a more concentrated focus on areas with better cash generation potential [10] Solar Business Growth - Primoris has grown its solar business from zero in 2017 to a $3 billion business today, although growth is expected to moderate in the near term [17][19] - The company anticipates a flat to slightly declining growth in solar for 2026 due to work being pulled forward from 2025 [19] Gas Generation Focus - The gas generation segment is currently around $400 million, with a focus on simple cycle projects, which are less risky and fit within the company’s operational capabilities [17][24] - Primoris has been able to attract talent and resources to support growth in this area, which was not initially factored into their strategic plan [20][21] Power Delivery Business - The power delivery segment constitutes about 45% of Primoris's utility segment, generating approximately $1.2 billion annually, primarily from distribution work [39] - There is a noted growth opportunity in transmission and substation work, although labor availability remains a constraint [40][41] Labor Availability Challenges - Labor availability, particularly for specialized roles like linemen, is a significant constraint on growth, prompting investments in training and recruitment [48][49] - Both companies are focusing on creating career paths and training programs to develop talent internally [53] Competitive Positioning - Primoris has maintained long-standing relationships with turbine suppliers, which has facilitated new project opportunities [44] - The company is positioned to benefit from a rising demand for electricity and the need for new power plants, particularly as older infrastructure approaches replacement cycles [33] Financial Outlook and Capital Allocation - Primoris is focused on organic growth as its primary capital allocation strategy, with a secondary focus on acquisitions in high-growth areas [63] - The company has a low leverage ratio and is well-positioned for potential acquisitions, although it prioritizes organic growth first [63] Other Important Insights - The telecom segment, while small, is seen as having growth potential, particularly with new leadership and opportunities in data centers and government contracts [35][36] - The midstream business, which had declined significantly during COVID-19, is showing signs of recovery, with expectations to reach $500-600 million by the end of the year [45] This summary encapsulates the key points discussed during the conference call, highlighting Primoris Services' strategic focus, business evolution, growth areas, challenges, and financial outlook.

Consumer Electronics Show Wednesday, January 7, 2026 Intelligent Security. Everywhere. © 2026 BlackBerry. All Rights Reserved © 2026 BlackBerry. All Rights Reserved 1 Safe Harbor Statement Some of the statements in this presentation constitute forward-looking statements and are made pursuant to the safe harbor provisions of applicable U.S. and Canadian securities laws. Forward-looking statements are indicated by using words such as expect, will, should, model, intend, believe and similar expressions. Forwar ...

Investor Presentation November 2025 Notice to Investors This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements give the current expectations of the Company's management. Words such as "anticipates", "believes", "could", "estimates", "expects", "intends", "may", "plans", "potential", "predicts", "projects", "should", "will", "would" and similar expressions are used to identify forward-looking statements. Without limiting the generality of the ...